170 related articles for article (PubMed ID: 37681986)
1. Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins.
Ganapathy US; Lan T; Dartois V; Aldrich CC; Dick T
Microbiol Spectr; 2023 Sep; 11(5):e0190023. PubMed ID: 37681986
[TBL] [Abstract][Full Text] [Related]
2. Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.
Ganapathy US; Lan T; Krastel P; Lindman M; Zimmerman MD; Ho H; Sarathy JP; Evans JC; Dartois V; Aldrich CC; Dick T
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0097821. PubMed ID: 34228543
[TBL] [Abstract][Full Text] [Related]
3. ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant
Xie M; Ganapathy US; Lan T; Osiecki P; Sarathy JP; Dartois V; Aldrich CC; Dick T
Antimicrob Agents Chemother; 2023 Sep; 67(9):e0038123. PubMed ID: 37493373
[TBL] [Abstract][Full Text] [Related]
4. Sudapyridine (WX-081) antibacterial activity against
Zheng L; Wang H; Qi X; Zhang W; Wang B; Fu L; Chen X; Chen X; Lu Y
mSphere; 2024 Feb; 9(2):e0051823. PubMed ID: 38240581
[TBL] [Abstract][Full Text] [Related]
5. Repositioning rifamycins for Mycobacterium abscessus lung disease.
Ganapathy US; Dartois V; Dick T
Expert Opin Drug Discov; 2019 Sep; 14(9):867-878. PubMed ID: 31195849
[No Abstract] [Full Text] [Related]
6. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591.
Rominski A; Roditscheff A; Selchow P; Böttger EC; Sander P
J Antimicrob Chemother; 2017 Feb; 72(2):376-384. PubMed ID: 27999011
[TBL] [Abstract][Full Text] [Related]
7. Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance.
Lan T; Ganapathy US; Sharma S; Ahn YM; Zimmerman M; Molodtsov V; Hegde P; Gengenbacher M; Ebright RH; Dartois V; Freundlich JS; Dick T; Aldrich CC
Angew Chem Int Ed Engl; 2022 Nov; 61(45):e202211498. PubMed ID: 36222275
[TBL] [Abstract][Full Text] [Related]
8. Kanglemycin A Can Overcome Rifamycin Resistance Caused by ADP-Ribosylation by Arr Protein.
Harbottle J; Mosaei H; Allenby N; Zenkin N
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0086421. PubMed ID: 34606341
[TBL] [Abstract][Full Text] [Related]
9. Modulation of a Mycobacterial ADP-Ribosyltransferase to Augment Rifamycin Antibiotic Resistance.
Zheng M; Lupoli TJ
ACS Infect Dis; 2021 Sep; 7(9):2604-2611. PubMed ID: 34355905
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the distribution of non-tuberculous mycobacteria strains isolated in National Tuberculosis Reference Laboratory in 2009-2010, Turkey].
Albayrak N; Simşek H; Sezen F; Arslantürk A; Tarhan G; Ceyhan I
Mikrobiyol Bul; 2012 Oct; 46(4):560-7. PubMed ID: 23188570
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of nontuberculous mycobacteria and high efficacy of d-cycloserine and its synergistic effect with clarithromycin against
Khosravi AD; Mirsaeidi M; Farahani A; Tabandeh MR; Mohajeri P; Shoja S; Hoseini Lar KhosroShahi SR
Infect Drug Resist; 2018; 11():2521-2532. PubMed ID: 30573983
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of PBTZ169 and pretomanid against Mycobacterium avium,
Zheng L; Qi X; Zhang W; Wang H; Fu L; Wang B; Chen X; Chen X; Lu Y
Front Cell Infect Microbiol; 2023; 13():1115530. PubMed ID: 37077530
[TBL] [Abstract][Full Text] [Related]
13. Real time PCR for the rapid identification and drug susceptibility of Mycobacteria present in Bronchial washings.
Keerthirathne TP; Magana-Arachchi DN; Madegedara D; Sooriyapathirana SS
BMC Infect Dis; 2016 Oct; 16(1):607. PubMed ID: 27782812
[TBL] [Abstract][Full Text] [Related]
14.
Aragaw WW; Cotroneo N; Stokes S; Pucci M; Critchley I; Gengenbacher M; Dick T
Microbiol Spectr; 2022 Feb; 10(1):e0132121. PubMed ID: 35019671
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of patients with non-tuberculous mycobacterial pulmonary disease: a seven-year follow-up study conducted in a certain tertiary hospital in Beijing.
Liu Q; Du J; An H; Li X; Guo D; Li J; Gong W; Liang J
Front Cell Infect Microbiol; 2023; 13():1205225. PubMed ID: 37424783
[TBL] [Abstract][Full Text] [Related]
16. A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus.
Ganapathy US; Del Río RG; Cacho-Izquierdo M; Ortega F; Lelièvre J; Barros-Aguirre D; Aragaw WW; Zimmerman MD; Lindman M; Dartois V; Gengenbacher M; Dick T
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0151421. PubMed ID: 34606340
[TBL] [Abstract][Full Text] [Related]
17. The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in
Luthra S; Rominski A; Sander P
Front Microbiol; 2018; 9():2179. PubMed ID: 30258428
[TBL] [Abstract][Full Text] [Related]
18. Non-tuberculous mycobacteria profiles and their anti-mycobacterial resistance at a major medical center in Lebanon.
Araj GF; Baba OZ; Itani LY; Avedissian AZ; Sobh GM
J Infect Dev Ctries; 2019 Jul; 13(7):612-618. PubMed ID: 32065818
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
[TBL] [Abstract][Full Text] [Related]
20.
Zhu R; Shang Y; Chen S; Xiao H; Ren R; Wang F; Xue Y; Li L; Li Y; Chu N; Huang H
Microbiol Spectr; 2022 Dec; 10(6):e0137222. PubMed ID: 36250885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
